At present, clinicians typically classify carcinomas into five subtypes (luminal A, luminal B HER2−, luminal B HER2+, HER2, and TN) on the basis of histologic and molecular characteristics, which notably include expression of the estrogen receptor (ER), progesterone receptor (PR), HER2, and Ki67. This evidence concerns the gene ERBB2 and carcinoma.